Relief is often more straightforward than patients expect, and it does not always require surgery
We're continually updating our protocols in line with the latest scientific understanding, ensuring that as of 2026, our GHK-Cu peptides meet and exceed industry expectations for purity and stability
Kinetic analysis of tyrosinase The mode of inhibition and inhibition parameters, i.e
Remains on Category 2 with no current PCAC referral
Glutathione might just be the secret ingredient you need
Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease